HACE1

Across TCGA pan-cancer cohorts, HACE1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HACE1 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher HACE1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated HACE1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where HACE1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	1.000	0.823	.007	17	view →
GBM	DFS	Tertile	All	0.475	0.248	.018	6	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	5	view →
OV	DFS	Median	All	1.000	0.665	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

HACE1–CCRCC (OS)

Open the CCRCC breakdown →